DE602006006558D1 - Verfahren zur verminderung von alpha, beta-ungesättigten ketonen in opioidzusammensetzungen - Google Patents

Verfahren zur verminderung von alpha, beta-ungesättigten ketonen in opioidzusammensetzungen

Info

Publication number
DE602006006558D1
DE602006006558D1 DE602006006558T DE602006006558T DE602006006558D1 DE 602006006558 D1 DE602006006558 D1 DE 602006006558D1 DE 602006006558 T DE602006006558 T DE 602006006558T DE 602006006558 T DE602006006558 T DE 602006006558T DE 602006006558 D1 DE602006006558 D1 DE 602006006558D1
Authority
DE
Germany
Prior art keywords
beta
unsaturated ketones
opioid compositions
preventing alpha
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006006558T
Other languages
English (en)
Inventor
Robert J Kupper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of DE602006006558D1 publication Critical patent/DE602006006558D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE602006006558T 2005-03-04 2006-02-27 Verfahren zur verminderung von alpha, beta-ungesättigten ketonen in opioidzusammensetzungen Active DE602006006558D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65879105P 2005-03-04 2005-03-04
PCT/EP2006/001798 WO2006094672A1 (en) 2005-03-04 2006-02-27 Method of reducing alpha, beta unsaturated ketones in opioid compositions

Publications (1)

Publication Number Publication Date
DE602006006558D1 true DE602006006558D1 (de) 2009-06-10

Family

ID=36301669

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602006018208T Active DE602006018208D1 (de) 2005-03-04 2006-02-27 Verfahren zur Verminderung von Alpha, Beta-ungesättigten Ketonen in Opioidzusammensetzungen
DE602006006558T Active DE602006006558D1 (de) 2005-03-04 2006-02-27 Verfahren zur verminderung von alpha, beta-ungesättigten ketonen in opioidzusammensetzungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE602006018208T Active DE602006018208D1 (de) 2005-03-04 2006-02-27 Verfahren zur Verminderung von Alpha, Beta-ungesättigten Ketonen in Opioidzusammensetzungen

Country Status (19)

Country Link
US (1) US7939543B2 (de)
EP (2) EP1861405B1 (de)
JP (1) JP5314894B2 (de)
KR (1) KR100941761B1 (de)
CN (1) CN101133062B (de)
AT (2) ATE487722T1 (de)
CA (1) CA2598774C (de)
CY (2) CY1109262T1 (de)
DE (2) DE602006018208D1 (de)
DK (2) DK2112153T3 (de)
ES (2) ES2326491T3 (de)
HK (2) HK1111695A1 (de)
HR (2) HRP20090387T1 (de)
ME (2) ME01594B (de)
PL (2) PL1861405T3 (de)
PT (2) PT2112153E (de)
RS (2) RS51568B (de)
SI (2) SI2112153T1 (de)
WO (1) WO2006094672A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
PT1842533E (pt) * 2003-08-06 2013-05-17 Gruenenthal Gmbh Forma de dosagem protegida contra abuso
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
TWI483944B (zh) 2004-03-30 2015-05-11 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
CN101395159A (zh) 2006-03-02 2009-03-25 马林克罗特公司 制备含有低含量α,β-不饱和酮化合物的吗啡烷-6-酮产物的方法
US7906647B2 (en) 2006-12-04 2011-03-15 Noramco, Inc. Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone
AU2007329451B2 (en) * 2006-12-04 2012-08-30 Noramco, Llc Process for reducing impurities in oxycodone base
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
CA2684458A1 (en) * 2007-04-16 2008-10-30 Mallinckrodt Inc. Novel opiate reduction utilizing catalytic hydrogen transfer reaction
FR2923484B1 (fr) * 2007-11-09 2012-11-09 Sanofi Aventis Procede de preparation de composes morphiniques
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
MX2010009990A (es) * 2008-03-11 2010-12-15 Depomed Inc Formas de dosificación gástricas retentivas de liberación prolongada que comprenden combinaciones de un analgésico no opioide y un analgésico opioide.
PT2273983T (pt) 2008-05-09 2016-10-28 Gruenenthal Gmbh Processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob utilização de uma etapa de congelamento por atomização
ES2560210T3 (es) * 2009-07-22 2016-02-17 Grünenthal GmbH Forma de dosificación resistente a la manipulación para opiádes sensibles a la oxidación
CN102573805A (zh) * 2009-07-22 2012-07-11 格吕伦塔尔有限公司 热熔挤出的控制释放剂型
RU2012112552A (ru) * 2009-08-31 2013-10-10 Дипомед, Инк. Удерживаемые в желудке фармацевтические композиции для немедленного и продленного высвобождения ацетаминофена
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
EP2377866B1 (de) 2010-03-23 2014-02-26 Siegfried AG Herstellung von opiaten hoher reinheit in einem durchflussreaktor
ES2645725T3 (es) 2010-06-11 2017-12-07 Rhodes Technologies Procesos catalizados por metales de transición para la preparación de compuestos de N-alilo y uso de los mismos
EP2580218B1 (de) 2010-06-11 2015-02-25 Rhodes Technologies Verfahren zur n-dealkylierung von tertiären aminen
RU2604676C2 (ru) 2010-09-02 2016-12-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль
TWI516286B (zh) 2010-09-02 2016-01-11 歌林達股份有限公司 含陰離子聚合物之抗破碎劑型
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
CN103857386A (zh) 2011-07-29 2014-06-11 格吕伦塔尔有限公司 提供药物立即释放的抗破碎片剂
LT2736495T (lt) 2011-07-29 2017-11-10 Grünenthal GmbH Sugadinimui atspari tabletė, pasižyminti greitu vaisto atpalaidavimu
JP6117249B2 (ja) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
CA2868142A1 (en) 2012-04-18 2013-10-24 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
EP2970320B1 (de) * 2013-03-15 2020-10-28 Johnson Matthey Public Limited Company Morphinsulfatmethanolsolvat, verfahren zur herstellung davon sowie zugehörige zusammensetzungen und verfahren zur behandlung von schmerzen
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
CN105682643B (zh) 2013-07-12 2019-12-13 格吕伦塔尔有限公司 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
US9062062B1 (en) 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride
US8846923B1 (en) 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
US10227354B2 (en) 2013-12-18 2019-03-12 Cody Laboratories, Inc. Conversion of oxycodone base to oxycodone hydrochloride
EP3142646A1 (de) 2014-05-12 2017-03-22 Grünenthal GmbH Manipulationssichere kapselformulierung mit tapentadol mit unmittelbarer freisetzung
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
CA2954600A1 (en) 2014-07-09 2016-01-14 Rhodes Technologies Reduction of alpha, beta-unsaturated ketone levels in morphinan derivative compositions
CN107889459A (zh) 2015-04-24 2018-04-06 格吕伦塔尔有限公司 具有立即释放和对溶剂萃取的抗性的抗篡改剂型
EP3346991A1 (de) 2015-09-10 2018-07-18 Grünenthal GmbH Schutz vor oraler überdosierung mit missbrauchssicheren formulierungen mit sofortiger freisetzung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3812312A (en) 1971-11-15 1974-05-21 Chrysler Corp Impact velocity sensor switch with linearly movable controller
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
GB9713703D0 (en) 1997-06-30 1997-09-03 Johnson Matthey Plc Preparation of opiates
US6177567B1 (en) * 1999-10-15 2001-01-23 Boehringer Ingelheim Chemicals, Inc. Method for preparing oxycodone
TWI483944B (zh) * 2004-03-30 2015-05-11 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝

Also Published As

Publication number Publication date
EP1861405A1 (de) 2007-12-05
KR100941761B1 (ko) 2010-02-11
SI1861405T1 (sl) 2009-10-31
WO2006094672A1 (en) 2006-09-14
EP2112153B1 (de) 2010-11-10
HK1135107A1 (en) 2010-05-28
ES2355870T3 (es) 2011-03-31
ATE430153T1 (de) 2009-05-15
RS51568B (en) 2011-08-31
CY1111241T1 (el) 2015-06-11
US7939543B2 (en) 2011-05-10
ATE487722T1 (de) 2010-11-15
DK2112153T3 (da) 2011-02-14
EP1861405B1 (de) 2009-04-29
ME01594B (me) 2014-09-20
CY1109262T1 (el) 2014-07-02
JP2008531626A (ja) 2008-08-14
SI2112153T1 (sl) 2011-02-28
CN101133062A (zh) 2008-02-27
DK1861405T3 (da) 2009-07-20
US20080132702A1 (en) 2008-06-05
CA2598774C (en) 2010-12-21
KR20070108931A (ko) 2007-11-13
RS51131B (sr) 2010-10-31
DE602006018208D1 (de) 2010-12-23
ES2326491T3 (es) 2009-10-13
JP5314894B2 (ja) 2013-10-16
HK1111695A1 (en) 2008-08-15
HRP20090387T1 (en) 2009-08-31
CN101133062B (zh) 2014-08-06
PT1861405E (pt) 2009-07-27
HRP20110078T1 (hr) 2011-03-31
PL2112153T3 (pl) 2011-04-29
PT2112153E (pt) 2010-12-17
PL1861405T3 (pl) 2009-10-30
ME01184B (me) 2013-03-20
CA2598774A1 (en) 2006-09-14
EP2112153A1 (de) 2009-10-28

Similar Documents

Publication Publication Date Title
DE602006006558D1 (de) Verfahren zur verminderung von alpha, beta-ungesättigten ketonen in opioidzusammensetzungen
DE602007003197D1 (de) Verfahren zur herstellung von morphinan-6-on-produkten mit geringen konzentrationen von alpha-, beta-ungesättigten ketonverbindungen
MA32301B1 (fr) 1-aryl-3-amino-alcoxypyrazoles comme ligands de sigma augmentant l'effet analgesique d'opioides et attenuant la dependance a ceux-ci
DE602006001854D1 (de) Zusammensetzungen und verfahren zur herstellung vo
ATE458535T1 (de) Verfahren zur herstellung von konzentrierten tensidzusammensetzungen
BRPI0913457B8 (pt) Composto e composição farmacêutica
ATE542803T1 (de) Verfahren zur herstellung von dihydrochinazolinen
DE502006000218D1 (de) Verfahren zur Herstellung von SiOC-verknüpften, linearen Polydialkylsiloxan-Polyoxyalkylen-Blockcopolymeren
DE602005023877D1 (de) Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide
EA201170295A1 (ru) ИНГИБИТОРЫ сМЕТ
ATE473224T1 (de) Verfahren zur herstellung von nebivolol
ATE543910T1 (de) Verfahren und materialien zur herstellung von simvastatin und verwandten verbindungen
DE602007003375D1 (de) Verfahren zur herstellung von 3(r)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicycloä2.2.2üoctanbromid
ATE529404T1 (de) Phenoxyessigsäuren als ppar-delta-aktivatoren
MX2011008885A (es) Composiciones, sintesis y metodos para usar derivados de arilpiperazina.
DE602006017011D1 (de) Verfahren zur Herstellung von Mannich Kondensationsprodukte zur Verwendung als Chelatbildner
WO2009154993A8 (en) Compositions, synthesis, and methods of using piperazine based antipsychotic agents
ATE526302T1 (de) Verfahren zur aufreinigung von hexafluorpropendimeren
DE502005009501D1 (de) Verfahren zur herstellung von candesartan
MX2011006845A (es) Inhibidores de glyt1 biciclicos 3.1.0 y metodos para elaboracion y utilizacion de los mismos.
ATE518910T1 (de) Phenolharz-aufweisende polymerzusammensetzung
DE502008001265D1 (de) Verwendung des pigd-proteins zur katalyse von 1,4-additionen von 2-oxoalkanoaten an alpha, beta-ungesättigte ketone
DK2038341T3 (da) Sammensætning med en polymer og en oxidationskatalysator
DK2004149T3 (da) Farmaceutiske sammensætninger indeholdende leflunomid
DE602007012989D1 (de) Verfahren zur Herstellung von Entacapon

Legal Events

Date Code Title Description
8364 No opposition during term of opposition